Walvax Biotech Terminates mRNA Vaccine Collaboration with Abogen Biosciences for COVID-19 and Shingles

36Kr learned that Walvax Biotechnology Co., Ltd. announced its decision, along with its subsidiary Yuxi Watson Biotechnology Co., Ltd., to terminate the technical development cooperation for the COVID-19 mRNA vaccine and the shingles mRNA vaccine with Abogen Biosciences. A "Termination Agreement" has been signed. After the termination of cooperation, all parties will settle the preliminary research, clinical, and other related expenses.Original Link